# Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

> **NCT00161655** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 60 (—)

## Conditions studied

- Psoriasis
- Arthritis, Psoriatic

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00161655
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-12
- **Target enrollment:** 60 (—)
- **Last updated:** 2009-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161655, "Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00161655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*